FGFR3 Mutation
Showing 1 - 25 of 6,258
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life
Active, not recruiting
- FGFR1 Gene Amplification
- +18 more
- Pemigatinib
- Quality-of-Life Assessment
-
Scottsdale, Arizona
- +5 more
Oct 18, 2022
Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Recruiting
- Bladder Cancer
- +12 more
-
Raleigh, North CarolinaxCures Virtual Site
Sep 20, 2021
Locally Advanced Unresectable Gastric Cancer Trial in Guangzhou (Pemigatinib)
Not yet recruiting
- Locally Advanced Unresectable Gastric Cancer
-
Guangzhou, Guangdong, ChinaCancer center of SunYat-sen University
Aug 11, 2023
Bladder Cancer Trial in Vandœuvre-lès-Nancy (Urine collection (150ml), Blood sample (20 ml))
Recruiting
- Bladder Cancer
- Urine collection (150ml)
- Blood sample (20 ml)
-
Vandœuvre-lès-Nancy, FranceInstitut de Cancérologie de Lorraine
Mar 23, 2022
Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification Trial in Tianjin (Pemigatinib)
Recruiting
- Solid Tumor
- +4 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Aug 28, 2023
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York
Recruiting
- Advanced Solid Tumor
- +13 more
- [225Ac]-FPI-1966
- +2 more
-
Duarte, California
- +3 more
Oct 25, 2022
Refractory Solid Tumors Trial in Seoul (pazopanib)
Completed
- Refractory Solid Tumors
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 13, 2022
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)
Not yet recruiting
- Locally Advanced Urothelial Carcinoma
- +3 more
- (no location specified)
Sep 15, 2022
Urinary Bladder Tumors, Tumor Metastasis, Ureteral Tumors Trial in New York, Myrtle Beach, Nashville (LOXO-435, Pembrolizumab)
Recruiting
- Urinary Bladder Neoplasms
- +2 more
-
New York, New York
- +2 more
Jan 31, 2023
Breast Cancer Trial in Guangzhou (Fulvestrant plus Anlotinib)
Recruiting
- Breast Cancer
- Fulvestrant plus Anlotinib
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 16, 2021
Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,
Recruiting
- Advanced Malignant Solid Neoplasm
- +9 more
- Everolimus
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
Gastrointestinal Cancer Trial in Tianjin (Pemigatinib)
Recruiting
- Gastrointestinal Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Dec 7, 2022
Acute Myeloid Leukemia With FLT3/ITD Mutation Trial (XY0206, Salvage Chemotherapy)
Not yet recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- XY0206
- Salvage Chemotherapy
- (no location specified)
May 24, 2023
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)
Not yet recruiting
- Advanced Solid Tumor
- +2 more
-
Palo Alto, California
- +9 more
Aug 2, 2022
Patterns Among PIK3CA Mutation in Advanced Breast Cancer
Completed
- Breast Cancer
-
East Hanover, New JerseyNovartis
Aug 1, 2023
NSCLC Metastatic Trial in Stockholm (Stereotactic body radiation therapy (SBRT), Temporary Stopping)
Recruiting
- Non-small Cell Lung Cancer Metastatic
- Stereotactic body radiation therapy (SBRT)
- Temporary Stopping
-
Stockholm, Solna, SwedenKarolinska University Hospital
Nov 9, 2023
Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation Trial in Baltimore (Recommendation for treatment with
Recruiting
- Metastatic Solid Tumor
- +4 more
- Recommendation for treatment with immunotherapy
-
Baltimore, MarylandJohns Hopkins University
Sep 8, 2022
Multiple Myeloma, Relapsed/Refractory Trial in Toronto (JNJ-42756493, Dexamethasone)
Terminated
- Multiple Myeloma
- Relapsed/Refractory
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Sep 15, 2020
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life
Recruiting
- Cancer
- +15 more
- Data collection and quality of life questionnaire
-
Graz, Austria
- +40 more
Jul 27, 2021
NSCLC Trial (Idylla EGFR_IUO/3.20 Mutation Test)
Not yet recruiting
- NSCLC
- Idylla EGFR_IUO/3.20 Mutation Test
- (no location specified)
Jul 24, 2023